NCSTN — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL33171	1.00	20/20
SCHEMBL137789	1.00	20/20
SCHEMBL139302	1.00	20/20
Mrk-560 (SCHEMBL237758)	1.00	20/20
Mrk-560 (SCHEMBL237759)	1.00	20/20
Mrk-560 (SCHEMBL237760)	1.00	20/20
SCHEMBL136503	0.76	20/20
SCHEMBL154957	0.66	20/20
SCHEMBL138898	0.66	20/20
SCHEMBL139605	0.66	20/20
Hydrochloric Acid (SCHEMBL154119)	0.65	20/20
SCHEMBL139065	0.64	20/20
SCHEMBL151407	0.62	20/20
SCHEMBL138968	0.61	20/20
SCHEMBL139498	0.60	20/20
SCHEMBL154717	0.58	20/20
SCHEMBL139470	0.58	20/20
SCHEMBL139515	0.58	20/20
SCHEMBL139460	0.58	20/20
SCHEMBL155625	0.57	20/20

Clinical trials — most relevant to NCSTN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome	PHASE4	COMPLETED
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB	PHASE2	COMPLETED
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
The Synapse Project	PHASE2	COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease	PHASE2	COMPLETED
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy	PHASE2	WITHDRAWN
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration	PHASE2	COMPLETED
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors	PHASE1	RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Neurological and Psychological Assessment of Neurocutaneous Syndromes in Upper Egypt Children	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Somatosensory Phenotype of Patients Suffering From Unspecific Neck and Arm Pain	nan	COMPLETED
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies	nan	COMPLETED
B3 for NMD: Bench to Bedside and Back	nan	ENROLLING_BY_INVITATION
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury	nan	COMPLETED
Susceptibility Genes in Autism Spectrum Disorders	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Ultrasound Guided Placental Growth Factor Vs Platelet Rich Plasma Injection in Peripheral Nerve Injury: an Interventional Study	nan	NOT_YET_RECRUITING
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients	nan	NOT_YET_RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NCSTN binder may also engage these)

Protein	Name	Similarity
P57716	—	1.000	P57716 →
Q8CGU6	—	1.000	Q8CGU6 →
Q6NZ07	—	0.992	Q6NZ07 →
Q8VCM8	—	0.988	Q8VCM8 →
Q5XIA1	—	0.987	Q5XIA1 →
Q5ZJH2	—	0.987	Q5ZJH2 →
NCLN	BOS complex subunit NCLN	0.986	landscape →
Q9GLD3	—	0.985	Q9GLD3 →
A0A8I3NGV2	—	0.983	A0A8I3NGV2 →
Q2V905	—	0.981	Q2V905 →
Q5RDH6	—	0.981	Q5RDH6 →
TFRC	Transferrin receptor protein 1	0.980	landscape →
Q07891	—	0.980	Q07891 →
Q8HZV3	—	0.976	Q8HZV3 →
ITGB4	Integrin beta-4	0.976	landscape →
Q7M758	—	0.976	Q7M758 →
Q6DYE8	—	0.975	Q6DYE8 →
Q9MYZ3	—	0.974	Q9MYZ3 →
A2A863	—	0.974	A2A863 →
Q28120	—	0.974	Q28120 →
Q6YAT4	—	0.973	Q6YAT4 →
Q8R4K8	—	0.973	Q8R4K8 →
Q9WTZ2	—	0.973	Q9WTZ2 →
Q62351	—	0.972	Q62351 →
PIGT	GPI-anchor transamidase component PIGT	0.972	landscape →
Q9CYK2	—	0.972	Q9CYK2 →
Q9UQQ1	—	0.971	Q9UQQ1 →
B2GUY2	—	0.971	B2GUY2 →
Q8BXQ2	—	0.971	Q8BXQ2 →
P55033	—	0.971	P55033 →